MD Carlos Eduardo Medina de la Garza
Phone Number: +52(81) 1340 4370 ext 1708 or 1730
An integral part of the Research and Development Center on Health Sciences (CIDICS), the Immunomodulators Unit recognizes immunomodulation as a specific research area to fulfill substantial contributions.
The laboratory is set to perform permanent evaluation of new or already know molecules that can perform as modifiers of immunologic response in medical therapy. Some of the objectives, among others, are to study anthelmintic and antiparasitic drugs with putative immunomodulatory properties such as levamisole, albendazole, ivermectin and diethylcarbamazine.
Diethylcarbamazine (DEC) is an anthelmintic derived from piperazine that has shown immunostimulatory properties including an increase in the adherence of granulocytes and plaques to the parasite. In this laboratory, modulatory properties of DEC have been analyzed regarding the immune and humoral cellular response, as well as the respiratory burst on a BALB/c mouse. Results suggest a stimulatory dosage-dependent effect of DEC, thus, it can be considered as a potential candidate for its usage as an immunologic modifier.
Methodology used for the evaluation processes for this kind of drugs is the measurement of respiratory outburst, cytokines expression, antibody production evaluation and evaluation in animals, amongst others. The services of this laboratory are sustained with Undergraduate and Postgraduate researchers/professors from the Medicine School and a Chemist specialized in basic research and highly qualified in operating the methodologies used for the evaluation of the immune system.
One of the therapeutic purposes of immunomodulation is the remediation of immunodeficiency conditions, mainly secondary immunodeficiency. Secondary immunodeficiencies are present on individuals with pathologies that affect one or more elements of the immune system; meaning that immunologic deficit is a secondary manifestation of an underlying disease (hereditary diseases, nutritional deficiencies, immunosuppressant agents, amongst others).
3D tissue culture biomimetize the morphologic and functional characteristics of an in vivo parental tissue. The development of an in vitro model of a swollen intestine based on human tissue can be a promising alternative to compliment the experimental systems existent for the monitoring and study of new therapeutic agents; these could help to determine the potential use of immunomodulatory substances against chronic inflammatory and autoimmune diseases.
This unit’s objective is the new therapeutic approach that function with known therapies to counteract diseases. The stimuli of the immunologic effectors in the host, different to the direct microbicide action of antibiotics, antivirals, and antifungal, represents an option to combat chronic pyogenic diseases.
This unit has the characteristics of a Level II biosafety laboratory. Basic equipment of a research laboratory such as:
As well as specialized technologies: